News
May 26, 2026
AbstractWild-type transthyretin cardiac amyloidosis (ATTRwt) is an underrecognized cause of heart failure that often mimics hypertensive or nonischemic…
May 25, 2026
AbstractTransthyretin amyloidosis (ATTR) is a rare, progressive, and fre- quently under-recognized systemic disease whose early clinical manifes- tations may…
May 22, 2026
TOPLINE:In patients newly diagnosed with cardiac amyloidosis (CA), continuous rhythm monitoring using implantable loop recorders found that clinically significant…
May 22, 2026
Cardiovascular diseases could be among the world’s first medical conditions to be treated by changing a patient’s genes. If ongoing phase 3 trials succeed, gene…
May 22, 2026
AbstractBackground and Purpose: Transthyretin (ATTR) amyloidosis, including wild-type (ATTRwt) and hereditary (ATTRv) forms, is a rare but increasingly recognized…
May 22, 2026
Introduction. Heart failure (HF) is a leading cause of hospitalization in Internal Medicine and HF with preserved ejection fraction (HFpEF) accounts for…
May 22, 2026
TARRYTOWN, N.Y., May 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive results from the Phase 1/2 LINKER-AL2…
May 21, 2026
join us for an informative, patient-centered webinar featuring cardiology and hematology experts, along with two patients sharing their lived experiences with…
May 21, 2026
AbstractThe therapeutic landscape for systemic immunoglobulin light chain (AL) amyloidosis has been revolutionized by daratumumab-based regimens, achieving 76% 5-…
May 21, 2026
At AstraZeneca, we turn ideas into life-changing medicines. Working here means being entrepreneurial, thinking big, and collaborating to make the impossible a…